Skip to main content

Table 1 Baseline, diagnostic and medication characteristics of the two study groups: cases suffering from dementia with Lewy bodies versus Alzheimer’s disease patients

From: Comorbidity profile in dementia with Lewy bodies versus Alzheimer’s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry

Characteristic Dementia with Lewy bodies Alzheimer’s disease Pvalue
(n=634) (n=9,161)
Gender    <0.001 a
Female 252 (39.7%) 5973 (65.2%)
Male 382 (60.3%) 3188 (34.8%)
Age (years) 76.5 (7.1) 77.6 (8.3) <0.001 b
MMSE score 21.4 (5.0) 21.5 (5.0) 0.593b
Body mass index (kg/m2) 24.4 (4.1) 24.3 (4.1) 0.565b
Living place    <0.001 a
Own house 559 (88.2%) 8627 (94.4%)
Nursing home 75 (11.8%) 512 (5.6%)
Co-resident    <0.001 a
Yes 218 (36.0%) 3879 (44.0%)
No 387 (64.0%) 4938 (56.0%)
Medication (at the time of diagnosis)   
Cholinesterase inhibitors 465 (73.6%) 6598 (72.7%) 0.272a
NMDA antagonist 95 (15.0%) 895 (9.9%) <0.001 a
Antidepressants 220 (34.8%) 2382 (26.3%) <0.001 a
Antipsychotics 103 (16.3%) 447 (4.9%) <0.001 a
Anxiolytics 84 (13.3%) 747 (8.2%) <0.001 a
Hypnotics 106 (16.8%) 1292 (14.2%) 0.065a
Cardiovascular drugs 365 (57.8%) 4825 (53.2%) 0.054a
Total number of drugs 4.7 (3.0) 3.7 (2.9) <0.001 b
  1. Data presented as number (%) or mean (standard deviation). Statistically significant differences (P≤0.05) in bold. MMSE, Mini-Mental State Examination; NMDA, N-methyl d-aspartate. aPearson chi-square statistic. bIndependent-sample t test.